



1 Reimbursement Recommendation

2 **Nab-Paclitaxel**

3 | Reimbursement request: For patients who developed
4 | hypersensitivity reactions (HSRs) to taxanes

5 | Draft Recommendation: Reimburse with conditions



Summary of Recommendation

The Formulary Management Expert Committee (FMEC) concluded that nab-paclitaxel is a reasonable alternative to taxanes in patients with taxane-induced hypersensitivity reactions (HSRs). FMEC reviewed several phase 3 randomized clinical trials noting at least comparable efficacy between nab-paclitaxel and taxanes in cancer treatments; however, these results were based on patients without prior HSRs.

FMEC considered nab-paclitaxel addresses patients' unmet needs by allowing treatment completion after HSRs in either adjuvant or advanced settings of cancer treatments.

The expected cost of nab-paclitaxel remains unknown as publicly available prices for this drug may not reflect current prices paid by public payers, and the price for nab-paclitaxel generic is not presently available.

FMEC concluded that nab-paclitaxel should be reimbursed for patients with Grade 2 or 3 moderate to severe HSRs, anaphylaxis or anaphylactoid reactions or significant contraindications to taxanes that are not manageable despite the use of premedications and increased infusion durations.



Therapeutic Landscape

What are Hypersensitivity Reactions to Taxanes?

Hypersensitivity reactions (HSRs) can occur in 10 to 15% of patients receiving taxane chemotherapies for the treatment of solid organ tumours such as breast cancer, non-small cell lung cancer, gastroesophageal cancer, and gynecological malignancies. The traditional taxanes—paclitaxel and docetaxel—contain diluents that improve solubility but can cause immediate HSRs in patients. Nab-paclitaxel is nanoparticle albumin-bound paclitaxel and does not contain the above diluents. Hence, the risk of HSRs with nab-paclitaxel is lower than with paclitaxel or docetaxel.

Why Did We Conduct This Review?

Public drug programs requested a Non-Sponsored Reimbursement Review and Recommendation of nab-paclitaxel in patients with HSRs to taxanes given variability in reimbursement across jurisdictions. Although most patients develop HSRs to taxanes for the treatment of breast cancers or gynecological cancers, the publicly funded drug programs requested a tumour agnostic approach, so nab-paclitaxel can be used as a treatment alternative for any taxanes-related HSRs.



Person with Lived Experience

A person with lived experience presented her journey with hypersensitive reactions to taxanes during treatment for stage 2 breast cancer. Following the initiation of docetaxel, she described her initial symptoms as having acidity in her stomach, feeling heat in her upper body and lower back pain. She then provided a detailed account of the desensitization process in which she experienced anaphylactic shock, hives and swelling in her face. After changing to nab-paclitaxel, she noted an improvement in her recovery from infusions, highlighting less fatigue and reduced reactions. She encouraged the committee to consider the delays to treatment and added challenges that hypersensitivity reactions cause, and that the treatment of these reactions further deteriorates a patient's well being, making chemotherapy more challenging to undergo. The most important outcomes to her included longevity so she could care for her child, as well as quality of life, underscoring the need for treatments that limit long term side effects, pain, and cognitive issues.



Stakeholder Feedback

What Did We Hear From Patients?

Hypersensitivity reactions (HSRs) to taxane chemotherapies significantly affect patients and their families. Patients reported a wide array of debilitating side effects from taxanes, including fatigue, infection risk, nerve damage, and emotional trauma and profound anxiety about subsequent treatments, leading to hospitalizations and affecting their work, family life, and overall quality of life. Patients who have faced severe immediate HSRs stressed the importance of having an alternative to traditional/standard of care taxanes that have similar benefits.

What Did We Hear From Clinicians?


Clinician groups noted that nab-paclitaxel represents an appealing alternative for patients who develop significant HSRs to traditional taxanes which cannot be managed despite premedication use. They noted that in some jurisdictions, the limited public reimbursement of nab-paclitaxel in some cancers leads to the exclusion of taxanes from the treatment regimen when patients develop HSRs to these drugs.

What Did We Hear From the Pharmaceutical Industry?

No input was provided from the pharmaceutical industry.

What Did We Hear From Public Drug Programs?

Public drug programs inquired about considerations for initiation and prescribing of therapy. Questions were asked regarding dosing equivalency, contraindications, and resource utilization.

 Refer to [Stakeholder Input](#) section of the clinical and pharmacoeconomic report.



Deliberation

With a unanimous vote, the Formulary Management Expert Committee (FMEC) concluded that nab-paclitaxel is a reasonable alternative to taxanes in certain circumstances such as hypersensitivity reactions. There is an expected benefit on reduced resource utilization and reduced patient burden on treatment. However, the cost implications remain unknown.

FMEC deliberated on the following 6 domains as illustrated in the Deliberative Framework (Figure 1):

- Clinical Value: whether the drug under review provides clinical value.
- Unmet Clinical Need: whether there is an unmet clinical need that available treatment(s) is/are not currently addressing.
- Comparable Efficacy: whether the drug under review is at least comparable to other available treatment(s) for the condition.
- Patient Values: whether the drug under review addresses patients' specific unmet needs and values.
- Health System & Social Considerations: whether there are health system or social considerations (e.g., administration, testing, equity, access, ethical) for the drug under review.
- Economic Implications: what are the economic implications of reimbursing the drug under review based on public list prices.

For this review, the 4 domains of clinical value, unmet clinical need, patient values, and health system & social considerations were the focus of FMEC's deliberation and reimbursement recommendation (Figure 1). The other 2 domains (comparable efficacy and economic implications), while discussed, were less of a focus of the deliberation.

Figure 1: Deliberative Framework

Alt Text: The committee deliberated on 6 domains: clinical value, unmet clinical need, comparable efficacy, patient values, health system & social considerations, and economic implications. The discussion of the 4 darker shaded domains of clinical value, unmet clinical need, patient values, and health system & social considerations contributed most to the deliberation and reimbursement recommendation by the committee. The 2 lighter shaded deliberative domains, comparable efficacy and economic implications, were a lesser focus of the deliberation.



Note: the darker shaded deliberative domains were considered most relevant, and the discussion of these domains contributed the most to the reimbursement recommendation by the committee. The lighter shaded domains were a lesser focus of the deliberation.

Decision Summary

Table 1: Why Did FMEC Make This Recommendation?

Domains	Reason
<p>Patient Values: whether the drug under review addresses patients' specific needs and values.</p>	<p>FMEC noted that patients are in favour of safely completing their intended treatments after experiencing a HSR to avoid missing or stopping treatment. Patients wish to minimize and avoid long infusion times required as part of desensitization protocols.</p>
<p>Clinical Value: whether the drug under review provides clinical value.</p> <p>Comparable Efficacy: whether the drug under review shows at least similar efficacy to other available treatments for the condition.</p>	<ul style="list-style-type: none"> • FMEC discussed that the presented evidence suggested that there is less risk for hypersensitivity reactions on nab-paclitaxel than on paclitaxel; however, these studies did not include patients with prior HSRs specifically and there is uncertainty in how the study results apply to this patient population. • The clinical experts reiterated that nab-paclitaxel is an albumin-bound form of paclitaxel that does not contain any diluent that is likely the cause of HSRs. Both paclitaxel and nab-paclitaxel contain the same drug, and only their formulations and adverse event profiles are different. • FMEC recognized that nab-paclitaxel is comparable to paclitaxel in terms of clinical efficacy based on some of the available studies that showed non inferiority efficacy for nab-paclitaxel compared to paclitaxel. • HSRs are less common with docetaxel, and limited data was presented on this drug. However, FMEC acknowledged that patients who experience HSRs to docetaxel should be managed similarly to those with HSRs to paclitaxel.
<p>Unmet Clinical Need: whether there is an unmet clinical need that available treatment(s) is/are not currently addressing.</p>	<ul style="list-style-type: none"> • FMEC recognized that HSRs are common in patients treated with taxanes. Although most reactions are mild or moderate, managing hypersensitivity reactions remains challenging for clinicians. • Without access to nab-paclitaxel, some patients are unable to continue taxane therapy either in the adjuvant setting when their treatment could be curative, or in the advanced setting when their treatment could prolong life.
<p>Health System & Social Considerations: whether there are health system or social considerations for the drug under review</p>	<ul style="list-style-type: none"> • FMEC recognized that there are equity issues with current public reimbursement to nab-paclitaxel for patients who are unable to receive taxanes across jurisdictions. • The current management of hypersensitivity reactions to taxanes involves desensitization or slower drug infusions which prolongs treatment times which patients have highlighted they would like to minimize.

Domains	Reason
	<ul style="list-style-type: none"> • Desensitization protocols and slower drug infusions increase the strain on nursing and pharmacy resources.
<p>Economic Implications: what are the economic implications of reimbursing the drug under review based on public list price</p>	<ul style="list-style-type: none"> • FMEC discussed the cost considerations associated with a reimbursement recommendation for nab-paclitaxel in patients with hypersensitivity reactions to taxanes. The committee noted that using publicly available pricing information, the combined drug acquisition and administration costs of treatment with nab-paclitaxel were similar to or less than the combined drug acquisition and administration costs of treatment of paclitaxel, but they were greater than the combined drug acquisition and administration costs of treatment of docetaxel. • The committee discussed that the publicly available price of paclitaxel may not represent the prices paid by public payers in Canada; as such, treatment costs associated with paclitaxel may be less than estimated, suggesting nab-paclitaxel may be associated with increased costs. • The committee also acknowledged the review report which noted the availability of a generic of nab-paclitaxel (for which no price was available at the time of the review), which should reduce the cost of nab-paclitaxel.

Full Recommendation

With a unanimous vote, FMEC recommends that nab-paclitaxel be reimbursed for patients who developed hypersensitivity reactions to taxanes if the conditions presented in Table 2 are met.

Table 2: Conditions, Reasons, and Guidance

Reimbursement condition	Reason	Implementation guidance
Initiation		
<p>Nab-paclitaxel should be reimbursed for patients who have one of the following characteristics:</p> <ul style="list-style-type: none"> • Grade 2 or 3 moderate to severe hypersensitivity reactions not manageable despite the use of premedications and infusion prolonging, • anaphylaxis or anaphylactoid reactions, • patients with significant contraindications to taxanes or premedications (e.g., high dose steroids) 	<p>Based on at least 6 Phase 3 randomized controlled studies comparing the use of nab-paclitaxel to paclitaxel, there is evidence to support that nab-paclitaxel is comparable to paclitaxel in the treatment of patients with various solid organ tumours (e.g., breast, lung, and gastroesophageal cancers).</p>	<p>Please refer to Severity Grading of Immediate Hypersensitivity Reactions table outlined in Table 3 on page 13 of the clinical report.</p> <p>Consider reimbursement of nab-paclitaxel for patients with contraindications to high-dose steroids such as in patients with difficult to control diabetes or steroid-induced neurocognitive changes.</p> <p>The dosing conversion between paclitaxel and nab-paclitaxel should be left to the discretion of treating clinicians and pharmacy teams.</p>
Discontinuation		
<p>Treatment and assessment should be continued as per usual practice.</p>	-	-
Prescribing		
<p>Nab-paclitaxel like other oncology drugs should be prescribed by a medical</p>	<p>Standard oncology operating procedures.</p>	-

Reimbursement condition	Reason	Implementation guidance
specialist with training in the diagnosis and management of cancer.		



Feedback on Draft Recommendation

<to be updated after the stakeholder feedback period.>

FMEC Information

Members of the committee: Dr. Emily Reynen (Chair), Dr. Alun Edwards, Ms. Valerie McDonald, Dr. Jim Silvius, Dr. Marianne Taylor, Dr. Maureen Trudeau, Dr. Dominika Wranik, Dr. James Biagi (guest specialist), and Dr. Danielle Desautels (guest specialist). 1 expert committee member did not attend.

Meeting date: May 10, 2024

Conflicts of interest: None

Special thanks: Canada's Drug Agency extends our special thanks to the individual who presented directly to FMEC on behalf of people with lived experience, as well as the patient organizations representing the community of those affected by hypersensitive reactions to taxanes, notably the Canadian Breast Cancer Network, which include JK Harris, Bukun Adegbebo and Milena Crosato.

The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Confidential information in this document may be redacted at the request of the sponsor in accordance with the CADTH Drug Reimbursement Review Confidentiality Guidelines. CADTH was established by Canada's federal, provincial, and territorial governments to be a trusted source of independent information and advice for the country's publicly funded health care systems. Health administrators and policy experts rely on CADTH to help inform their decisions about the life cycle management of drugs, devices, and services used to prevent, diagnose, and treat medical conditions.



CADTH was established by Canada's federal, provincial, and territorial governments to be a trusted source of independent information and advice for the country's publicly funded health care systems. Health administrators and policy experts rely on CADTH to help inform their decisions about the life cycle management of drugs, devices, and services used to prevent, diagnose, and treat medical conditions.

CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

cadth.ca

January 2024